PLUR vs. SRZN, NKGN, INKT, TARA, ACHL, CRTX, CASI, BCLI, ESLA, and SABS
Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Surrozen (SRZN), NKGen Biotech (NKGN), MiNK Therapeutics (INKT), Protara Therapeutics (TARA), Achilles Therapeutics (ACHL), Cortexyme (CRTX), CASI Pharmaceuticals (CASI), Brainstorm Cell Therapeutics (BCLI), Estrella Immunopharma (ESLA), and SAB Biotherapeutics (SABS). These companies are all part of the "medical" sector.
Surrozen (NASDAQ:SRZN) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
Surrozen has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Pluri has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.
Surrozen received 3 more outperform votes than Pluri when rated by MarketBeat users.
Pluri has lower revenue, but higher earnings than Surrozen.
Surrozen has a net margin of 0.00% compared to Surrozen's net margin of -6,339.59%. Pluri's return on equity of -85.54% beat Surrozen's return on equity.
In the previous week, Pluri had 1 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for Pluri and 1 mentions for Surrozen. Pluri's average media sentiment score of 1.39 beat Surrozen's score of 0.35 indicating that Surrozen is being referred to more favorably in the media.
66.6% of Surrozen shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 43.5% of Surrozen shares are held by company insiders. Comparatively, 10.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Surrozen beats Pluri on 7 of the 12 factors compared between the two stocks.
Get Pluri News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
